Ipamorelin vs CJC-1295
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. |
Frequently Asked Questions: Ipamorelin vs CJC-1295
What is the difference between Ipamorelin and CJC-1295?
Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or CJC-1295?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while CJC-1295 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and CJC-1295 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and CJC-1295 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.